Orient Biotech(688298)2025-04-29 16:50Financial Performance - The company's operating revenue for Q1 2025 was ¥191,951,815.38, representing a 4.94% increase compared to ¥182,922,481.69 in the same period last year[4] - The net profit attributable to shareholders was -¥115,452,483.95, a decrease of 71.41% from -¥67,353,495.40 year-over-year[4] - The basic and diluted earnings per share were both -¥0.57, a decline of 72.73% compared to -¥0.33 in the same period last year[4] - The weighted average return on equity was -1.75%, down from -0.91% year-over-year[4] - Net loss for Q1 2025 was CNY 120,770,122.94, compared to a net loss of CNY 69,955,283.74 in Q1 2024, representing an increase in loss of 72.6%[20] - Operating profit for Q1 2025 was CNY -123,486,375.38, worsening from CNY -67,454,742.43 in Q1 2024[19] - The company reported a total comprehensive loss of CNY -128,591,327.44 for Q1 2025, compared to CNY -78,308,185.85 in Q1 2024[20] Cash Flow - The net cash flow from operating activities improved by 74.38%, reaching -¥54,288,610.17, compared to -¥211,864,976.91 in the previous year[4] - Operating cash inflow totaled 228,718,943.11 in the previous period, reflecting a growth of approximately 20.8%[24] - Cash inflow from investment activities reached 539,083,927.86 in the prior period, marking an increase of about 172.6%[25] - Cash inflow from financing activities amounted to 105,960,000.00, representing an increase of approximately 125%[25] - The ending cash and cash equivalents balance was 2,595,292,577.44 year-over-year[25] Assets and Liabilities - Total assets decreased by 4.14% to ¥7,759,161,951.63 from ¥8,094,580,246.54 at the end of the previous year[5] - The company reported a total current assets of RMB 3,583,909,471.49 as of March 31, 2025, down from RMB 3,978,764,707.92 at the end of 2024, representing a decrease of approximately 9.9%[14] - Total liabilities decreased to CNY 1,094,430,122.43 in Q1 2025 from CNY 1,303,147,089.90 in Q1 2024, a decline of 15.9%[16] - The company's total equity decreased to CNY 6,664,731,829.20 in Q1 2025 from CNY 6,791,433,156.64 in Q1 2024, a decrease of 1.9%[16] Research and Development - Research and development expenses totaled ¥58,725,780.47, accounting for 30.59% of operating revenue, down from 39.34% in the previous year[5] - Research and development expenses for Q1 2025 were CNY 58,725,780.47, down 18.3% from CNY 71,964,517.95 in Q1 2024[19] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 13,778[9] - The top three shareholders collectively hold 48.56% of the company's shares, with Anji Fulanglai holding 19.5%, Fangs Holdings Limited at 18.75%, and Anji Yongwei at 10.31%[11] - The company has not reported any changes in the participation of major shareholders in margin trading or securities lending activities[12] Legal Matters - The company is currently facing a lawsuit from FS Medical Supplies, LLC, claiming damages not less than USD 1 billion, along with additional compensatory damages of at least USD 250 million[12] - The company has engaged legal counsel to respond to the lawsuit and is also pursuing legal action against FS Medical Supplies, LLC in China[13] - As of the report date, the lawsuit has not impacted the company's financial results for the reporting period[13] Inventory and Receivables - Cash and cash equivalents decreased to RMB 2,604,809,193.17 from RMB 3,081,496,804.80, reflecting a decline of about 15.4%[14] - Accounts receivable decreased to RMB 191,096,239.50 from RMB 228,082,280.19, a reduction of about 16.2%[14] - Inventory decreased slightly to RMB 296,948,644.63 from RMB 308,960,712.66, indicating a decrease of around 3.9%[14]